vimarsana.com

Page 6 - Jsonnet News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sonnet BioTherapeutics, Inc : Sonnet BioTherapeutics Announces Positive Results from a Preclinical Combination Study of SON-1010 with anti-PD1 Checkpoint Inhibition

Tumor volume growth inhibition improvements observed with the combination of SON-1010 (IL12-FHAB) and a commercially available anti-PD1 antibodyCombination of SON-1010 with anti-PD1 increased survival

Michaelv morabitoPankaj mohanJohn ciniExchange commissionSonnet biotherapeutics incSecurities exchangeSonnet biotherapeutics holdings incFully human albuminSonnet founderChief executive officerStudy designTmean comparisonsTumor volume growthChief scientificFully human albumin bindingSecurities act

Sonnet BioTherapeutics, Inc : Sonnet BioTherapeutics Announces Adjournment of Annual Meeting Due to Lack of Quorum

PRINCETON, NJ / ACCESSWIRE / June 2, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, today

Michaelv morabitoExchange commissionExchange commission onSonnet biotherapeutics incSecurities exchangeSonnet biotherapeutics holdings incAnnual meetingEastern timeFully human albumin bindingSecurities actSecurities exchange actPrivate securities litigation reform act

Sonnet BioTherapeutics, Inc : Sonnet BioTherapeutics Provides Fiscal Year 2022 Second Quarter Business and Earnings Update

IND for SON-1010 cleared by FDA with first patient dosed in trial for advanced solid tumorsSON-080 on track to begin clinical studies by mid-2022Preclinical data for SON-1010, SON-1210, and SON-1410 presented

Michaelv morabitoJay crossPankaj mohanExchange commissionSonnet biotherapeutics incSecurities exchangeSonnet biotherapeutics holdings incFully human albumin bindingRecent corporateQuarter ended marchSecurities actSecurities exchange actPrivate securities litigation reform act

Sonnet BioTherapeutics, Inc : Sonnet BioTherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of SON-1010 for Advanced Solid Tumors

PRINCETON, NJ / ACCESSWIRE / April 13, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that dosing has

United statesSant chawlaMichaelv morabitoPankaj mohanRichard kenneyExchange commissionPrincipal investigator at sarcoma oncology centerSonnet biotherapeutics incSecurities exchangeSonnet biotherapeutics holdings incFully human albumin bindingChief medicalSonnet founderChief executivePrincipal investigatorSarcoma oncology center

Sonnet BioTherapeutics, Inc : Sonnet BioTherapeutics Announces Preclinical Data Supporting Its Bispecific Interleukin Candidates at the American Association for Cancer Research 2022 Annual Meeting

PRINCETON, NJ / ACCESSWIRE / April 8, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that data from preclinical

United statesNew orleansNew orleans convention centerMichaelv morabitoJohn ciniExchange commissionOrleans convention centerAmerican association for cancer researchSonnet biotherapeutics incSecurities exchangeSonnet biotherapeutics holdings incFully human albumin bindingAmerican associationCancer researchAnnual meetingScientific officer

vimarsana © 2020. All Rights Reserved.